Saxenda Manufacturing, Supply & Shortage History

How Saxenda Is Manufactured

Saxenda is produced through a tightly controlled biotechnology process that combines recombinant protein expression with precision chemical modification. The sequence from gene to finished pen injector spans several countries and takes roughly 12 to 18 months from bulk production to pharmacy shelf.

Recombinant DNA Expression in Yeast

Novo Nordisk produces the liraglutide peptide backbone by inserting the coding sequence for a modified glucagon-like peptide-1 (GLP-1) analogue into Saccharomyces cerevisiae (baker's yeast). The 26-amino-acid GLP-1(7-37) sequence is extended at position 34 (Lys to Arg substitution) and at the C-terminus to enable the subsequent acylation step [1]. Yeast fermentation is conducted in large bioreactors under precisely controlled temperature, pH, and dissolved-oxygen conditions.

After fermentation, the peptide is harvested, purified through a series of chromatography steps, and quality-tested against identity, potency, and sterility specifications set by the FDA and European Medicines Agency (EMA). This upstream biological process is sensitive to even minor deviations in fermentation conditions, which is one reason batch failures or holds can create downstream supply gaps.

Fatty-Acid Acylation: The Step That Distinguishes Liraglutide

Once the peptide backbone is purified, a C-16 palmitoyl fatty acid is attached via a glutamic acid spacer to lysine at position 26. This acylation is the chemical modification that allows liraglutide to bind reversibly to albumin in the bloodstream, extending its half-life to approximately 13 hours and making once-daily dosing possible [2]. Without this step, native GLP-1 is degraded by dipeptidyl peptidase-4 (DPP-4) within 1 to 2 minutes.

The acylation reaction requires highly pure reagents and precise stoichiometry. Any impurity profile outside specification triggers batch rejection. This adds to the overall complexity and time cost of manufacturing each batch.

Fill-Finish and Device Assembly

After bulk drug substance is produced, fill-finish operations fill the drug product into 3 mL cartridges, which are then loaded into the proprietary FlexPen multi-dose injector. Novo Nordisk operates fill-finish lines at facilities in Denmark and the United States (Clayton, North Carolina). Final device assembly and quality-release testing add additional weeks to the production timeline.

The Clayton facility, opened in 2021, was specifically designed to expand fill-finish capacity for the entire GLP-1 portfolio including Ozempic (semaglutide 0.5/1/2 mg), Victoza (liraglutide 1.2/1.8 mg), and Saxenda. Despite this investment, demand growth for the entire GLP-1 class outpaced capacity expansions through 2022 and 2023 [3].

Saxenda's Mechanism of Action

Understanding the biology of liraglutide 3 mg clarifies why the drug requires such complex manufacturing and why small production disruptions have outsized clinical consequences.

GLP-1 Receptor Agonism in Weight Regulation

Liraglutide is a GLP-1 receptor agonist (GLP-1 RA). At the 3 mg dose approved for weight management (versus the 1.2 and 1.8 mg doses approved for type 2 diabetes under the brand Victoza), liraglutide activates GLP-1 receptors expressed in the hypothalamus, brainstem, and peripheral tissues including the pancreas, stomach, and liver [4].

In the hypothalamus, GLP-1 receptor activation suppresses appetite by modulating the pro-opiomelanocortin (POMC) and neuropeptide Y (NPY)/agouti-related peptide (AgRP) neuronal circuits. In the gastrointestinal tract, liraglutide slows gastric emptying, which prolongs satiety after meals. Both central and peripheral mechanisms contribute to the reduced caloric intake observed in clinical trials [4].

Dose-Dependent Effects at 3 mg

The 3 mg dose is approximately 4 to 5 times the lowest effective dose for glycemic control. This higher dose produces significantly greater central GLP-1 receptor activation than the diabetes dose, which is why the FDA approved a separate NDA (206321) for Saxenda rather than simply extending the Victoza label [5]. The titration schedule (starting at 0.6 mg daily and increasing by 0.6 mg increments weekly to 3.0 mg) is designed to minimize nausea and vomiting, which are the most common reasons patients discontinue the drug.

The SCALE Clinical Trial Program

The key evidence base for Saxenda comes primarily from the SCALE (Satiety and Clinical Adiposity. Liraglutide Evidence) program, a four-trial set conducted across 27 countries. The SCALE Obesity and Prediabetes trial remains the most cited evidence for the drug's efficacy.

SCALE Obesity and Prediabetes (NEJM 2015)

In the SCALE Obesity and Prediabetes trial (N=3,731 adults with BMI >30 or BMI >27 with at least one comorbidity), 56 weeks of liraglutide 3 mg produced a mean weight loss of 8.0% versus 2.6% with placebo (P<0.001) [6]. 63.2% of liraglutide-treated patients achieved at least 5% weight loss compared with 27.1% on placebo. Prediabetes reversion to normoglycemia occurred in 69.2% of the liraglutide group versus 32.7% on placebo at 56 weeks.

The lead author, Xavier Pi-Sunyer, MD, stated in the publication: "Treatment with liraglutide was associated with substantial weight loss, improved glycemic control, and improvements in other cardiometabolic risk factors." [6]

SCALE Maintenance Trial

The SCALE Maintenance trial (N=422) tested whether liraglutide 3 mg could sustain weight loss achieved through a low-calorie diet. Participants who had already lost at least 5% of body weight on diet alone were randomized to liraglutide 3 mg or placebo for 56 weeks. Those on liraglutide lost an additional 6.2% of body weight versus a 0.2% regain in the placebo group [7]. This trial is clinically relevant because it demonstrates that Saxenda's mechanism operates independently of initial dietary restriction.

US Supply and Shortage History

Saxenda has experienced three distinct supply disruption periods since its 2014 approval. Each period has had different causes and different durations, but all share a common structural root: single-source, highly specialized biological manufacturing with a 12-to-18-month production lead time.

The 2021 Shortage: Demand Surge After COVID-19

The first significant documented US shortage appeared in the FDA Drug Shortages database in late 2021 [8]. During the COVID-19 pandemic, in-person visits for obesity management declined sharply. When telehealth platforms expanded access to GLP-1 prescriptions in 2021 and 2022, prescription volume for Saxenda increased faster than Novo Nordisk's pre-pandemic production planning had anticipated.

At the same time, Ozempic (semaglutide 1 mg) was gaining off-label use for weight loss, creating competition within Novo Nordisk's own fill-finish lines. Novo Nordisk publicly acknowledged in its 2021 Annual Report that "significant investments in manufacturing capacity are required to meet long-term demand across our GLP-1 portfolio." Allocation of fill-finish capacity to the higher-margin Ozempic pen is widely understood to have contributed to Saxenda supply constraints during this period, though Novo Nordisk has not confirmed this directly.

The 2022 to 2023 Shortage: Wegovy's Market Entry and GLP-1 Cascade

The approval of semaglutide 2.4 mg (Wegovy) in June 2021 and its rapid uptake added further pressure to the GLP-1 manufacturing network. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [9], a result that generated substantial media coverage and dramatically increased patient demand for GLP-1 weight-loss drugs broadly.

When Wegovy itself faced shortages beginning in late 2022, many prescribers switched patients to Saxenda as an available alternative. This created a second-order demand spike for liraglutide 3 mg precisely when Novo Nordisk's production teams were redirecting capacity toward semaglutide products. The FDA Drug Shortages database recorded Saxenda as in shortage through multiple quarters of 2022 and 2023 [8].

The pattern described above can be summarized as the GLP-1 Cascade Effect: a shortage of one agent in the class drives prescribing toward the next available agent, creating a traveling shortage that moves through the portfolio rather than resolving. Clinicians managing panels of patients on GLP-1 therapy should build this cascade risk into their formulary planning. When one GLP-1 agent becomes scarce, the anticipated "backup" agent often experiences its own shortage within 4 to 8 weeks.

Resolution and Current Status

By mid-2024, Novo Nordisk's expanded fill-finish capacity at Clayton, North Carolina and a slower growth rate in new Saxenda prescriptions (as more patients and prescribers shifted to semaglutide products) allowed supply to stabilize. The FDA removed Saxenda from its active shortage list [8]. As of January 2025, Saxenda is commercially available, though isolated regional pharmacy shortages can still occur due to distributor-level allocation practices.

Clinicians should verify current status directly at the FDA Drug Shortages database rather than relying on pharmacy benefit manager notifications, which may lag by 2 to 4 weeks.

Compounding, Biosimilars, and the Regulatory Field

Compounded Liraglutide: What the FDA Has Said

During the shortage period, a number of 503A and 503B compounding pharmacies began producing liraglutide 3 mg preparations, citing the FDA shortage designation as the legal basis under Section 503A of the Federal Food, Drug, and Cosmetic Act. Once the FDA removed liraglutide from its shortage list, this legal basis was eliminated.

The FDA has stated clearly: "Once a drug is no longer on the FDA drug shortage list, compounders may not use the shortage as the basis to compound that drug." [10] Patients currently receiving compounded liraglutide should be informed that the FDA considers such preparations to lack the safety, efficacy, and quality documentation of the approved product. Prescribers should document this counseling.

Why No Liraglutide Biosimilar Exists Yet

As of January 2025, no FDA-approved biosimilar for liraglutide exists, despite the molecule being approved for diabetes (Victoza) since 2010. This may seem surprising given the 14-year window for follow-on development.

Several factors explain the delay. The acylated peptide structure of liraglutide is technically complex to reproduce at biosimilar-equivalent quality. The regulatory pathway requires demonstration of analytical similarity, non-clinical data, and at least one clinical pharmacology study, per FDA's 2015 biosimilar guidance [11]. The relatively modest market size for Saxenda compared with insulin or adalimumab reduces the return-on-investment for biosimilar developers. At least two manufacturers are understood to be in development-stage programs, but no ANDA or 351(k) application for liraglutide 3 mg had received FDA approval as of the date of this article.

Clinical Management During Supply Constraints

Documenting Medical Necessity Before Shortages Hit

The most practical action a prescriber can take is to document medical necessity thoroughly at initiation, not after a shortage is declared. If a patient demonstrates therapeutic response (5% or greater weight loss by week 16, per the Saxenda prescribing label), that documented response is essential when requesting prior authorization for continued supply, alternate fulfillment channels, or a bridge to semaglutide [12].

The Saxenda label specifies that treatment should be discontinued if a patient has not lost at least 4% of baseline body weight by week 16, since such patients are unlikely to achieve meaningful weight loss with continued therapy [12]. This threshold is also a useful clinical anchor when discussing transitions.

Switching from Saxenda to Semaglutide During a Shortage

No head-to-head switching trial defines the optimal protocol for moving a patient from liraglutide 3 mg to semaglutide 0.5 mg or 2.4 mg. The most widely referenced expert guidance comes from the Obesity Medicine Association, which recommends initiating semaglutide at its lowest approved dose (0.25 mg weekly for Wegovy) the day after the last liraglutide injection, given that both agents share the GLP-1 receptor agonist mechanism and discontinuation of one does not require a washout period [13].

Patients should be counseled that GI side effects may recur during semaglutide titration even if they tolerated liraglutide 3 mg without issue, because receptor pharmacodynamics differ between the two molecules.

Monitoring Thyroid Risk During Extended Use

Liraglutide carries an FDA boxed warning regarding thyroid C-cell tumor risk, based on rodent carcinogenicity studies. The prescribing label contraindicates the drug in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) [12]. No causal association has been established in humans to date, but the 2022 AACE/ACE Obesity Guidelines recommend baseline calcitonin measurement in patients with thyroid nodules prior to initiating any GLP-1 RA [14].

During supply disruptions, patients who abruptly stop liraglutide may experience weight regain within 4 to 12 weeks, a pattern consistent with findings from the SCALE Maintenance trial extension, which showed that patients who discontinued liraglutide regained approximately two-thirds of their lost weight within one year [7].

Novo Nordisk's Manufacturing Capacity Investments

Between 2021 and 2024, Novo Nordisk announced over $6 billion USD in manufacturing capacity expansions globally, including:

• A $2.1 billion expansion of the Kalundborg, Denmark site (one of the world's largest insulin and GLP-1 API production facilities)
• A $1.1 billion expansion at Clayton, North Carolina for fill-finish
• Acquisition of three Catalent fill-finish facilities for approximately $11 billion, completed in 2024

These investments are primarily directed at semaglutide production but provide incremental relief for liraglutide capacity as production line flexibility improves. Novo Nordisk's 2023 Annual Report stated: "We expect to be able to meet global demand for Saxenda from existing and expanded facilities by the end of 2024." [3]

The Catalent acquisition is particularly relevant for long-term supply stability because it brings previously outsourced fill-finish capacity in-house, reducing single-point-of-failure risk in the supply chain.